Related Experiment Video
Updated: Dec 15, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
New targets and technologies for CAR-T cells
Fabian Freitag1, Marius Maucher, Zeno Riester
1Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Purpose Of Review:
Immunotherapy with gene-engineered chimeric antigen receptor (CAR)-T cells has curative potential in advanced malignancies and undergoes a surging preclinical and clinical development. Here, we present a selection of new targets and technologies that illustrate the progress that is being made with the aspiration to make CAR-T cell therapy a universally applicable and effective treatment in cancer medicine.
Recent Findings:
There is a rich pipeline of new target antigens for CAR-T cells in hematology and oncology that are rated based on uniformity but also stability of expression on tumor cells under therapeutic pressure. New technologies in CAR-T cell engineering are directed at neutralizing inhibitory ligands and factors in the tumor microenvironment, preventing CAR-T cell exhaustion and enhancing selectivity for tumor cells with 'smart' CAR designs. The manufacture of CAR-T cells using virus-free protocols is anticipated to reduce supply-chain complexity and to improve patient access.
Summary:
CD19 CAR-T cell therapy is an approved treatment for B-cell leukemia and -lymphoma and considering the current 'target and technology' pipeline, we anticipate that additional CAR-T cell products will accomplish their 'breakthrough' and clinical proof-of-concept in other indications in hematology and in oncology. Technologies to enhance therapeutic index and facilitate manufacturing will be key for assuring availability and accessibility of CAR-T cell products and their implementation into routine clinical practice.
Insights
Chimeric antigen receptor (CAR)-T cell therapy shows promise for treating advanced cancers. New targets and technologies are improving CAR-T cell effectiveness, accessibility, and application in broader cancer medicine.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR)-T cell immunotherapy is a rapidly advancing field with significant potential for treating advanced cancers.
- Current CAR-T cell therapies are primarily focused on hematological malignancies, with ongoing research exploring broader applications.
Purpose of the Study:
- To review emerging targets and innovative technologies in CAR-T cell therapy development.
- To highlight advancements aimed at making CAR-T cell therapy a more universally applicable and effective cancer treatment.
Main Methods:
- Review of current preclinical and clinical research on novel CAR-T cell targets and engineering strategies.
- Analysis of new technologies designed to overcome challenges in the tumor microenvironment and enhance CAR-T cell function.
- Evaluation of advancements in CAR-T cell manufacturing, including virus-free protocols.
Main Results:
- Identification of a robust pipeline of new target antigens for CAR-T cells, with emphasis on expression uniformity and stability.
- Development of 'smart' CAR designs and strategies to neutralize inhibitory tumor microenvironment factors, mitigating CAR-T cell exhaustion.
- Progress in virus-free CAR-T cell manufacturing to simplify supply chains and improve patient access.
Conclusions:
- CAR-T cell therapy, exemplified by CD19-targeted treatments, is poised for expansion into new hematological and oncological indications.
- Technological innovations enhancing the therapeutic index and manufacturing efficiency are crucial for widespread clinical adoption and accessibility of CAR-T cell products.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...